Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  American journal of ophthalmology-glaucoma

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ajo.2011.07.005PMID 21930258
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity.

  2011cited by this paper
• Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

  2011cited by this paper
• Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.

  2011cited by this paper
• Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.

  2010cited by this paper
• Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity.

  2009cited by this paper
• Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.

  2009cited by this paper
• Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity.

  2009cited by this paper
• INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN) FOR TREATMENT OF STAGE 3 RETINOPATHY OF PREMATURITY IN ZONE I OR POSTERIOR ZONE II

  2008cited by this paper
• VEGF-A, VEGFR-1, VEGFR-2 and Tie2 levels in plasma of premature infants: relationship to retinopathy of prematurity

  2008cited by this paper
• Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study

  2008cited by this paper
• Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity.

  2008cited by this paper
• Complications in patients after intravitreal injection of bevacizumab

  2008cited by this paper
• Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.

  2008cited by this paper
• Pharmacokinetics of intravitreal bevacizumab (Avastin).

  2007cited by this paper
• Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.

  2006cited by this paper
• Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

  2006cited by this paper
• [IGF-I, VEGF and bFGF as predictive factors for the onset of retinopathy of prematurity (ROP)].

  2006cited by this paper
• Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy.

  2006cited by this paper
• The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

  2006cited by this paper
• IGF-I, VEGF Y bFGF, COMO FACTORES PRONÓSTICOS DE LA APARICIÓN DE LA RETINOPATÍA DE LA PREMATURIDAD IGF-I, VEGF AND bFGF AS PREDICTIVE FACTORS FOR THE ONSET OF RETINOPATHY OF PREMATURITY (ROP)

  2006cited by this paper
• Early vitreous surgery for aggressive posterior retinopathy of prematurity.

  2006cited by this paper
• The International Classification of Retinopathy of Prematurity revisited.

  2005cited by this paper
• Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro

  2004cited by this paper
• FEATURES ASSOCIATED WITH SURGICAL OUTCOME IN PATIENTS WITH STAGES 4 AND 5 RETINOPATHY OF PREMATURITY

  2003cited by this paper
• Retinopathy of Prematurity

  2003cited by this paper
• Retinopathy of prematurity: molecular pathology and therapeutic strategies.

  2003cited by this paper
• Blood-retinal barrier breakdown caused by diode vs argon laser endophotocoagulation.

  1992cited by this paper

• Impact of anti‐VEGF therapy versus laser therapy on mortality and treatment outcomes in retinopathy of prematurity: A systematic review and meta‐analysis

  2025cites this paper
• Reactivation of retinopathy of prematurity after anti-VEGF treatment: a review

  2025cites this paper
• Consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME).

  2025cites this paper
• A meta-analysis of intravitreal ranibizumab versus laser photocoagulation for the treatment of retinopathy of prematurity.

  2025cites this paper
• Serine supplementation suppresses hypoxia-induced pathological retinal angiogenesis

  2025cites this paper
• Different ranibizumab dosages for retinopathy of prematurity: 5-year follow-up data of the randomised, controlled CARE-ROP Study

  2025cites this paper
• Update on Management of Retinopathy of Prematurity: A Review

  2024cites this paper
• ADMINISTERING INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY

  2024cites this paper
• Recurrence of Retinopathy of Prematurity Following Anti-vascular Endothelial Growth Factor (Anti-VEGF) Therapy: A Systematic Review and Meta-Analysis

  2024cites this paper
• Dose-Reduction of Bevacizumab in Atezolizumab plus Bevacizumab Therapy Extends Treatment duration with Disease Control in Patients with Hepatocellular Carcinoma

  2024cites this paper
• Relations between Neurocognitive Function and Visual Acuity: A Cross-Sessional Study in a Cohort of Premature Children

  2024cites this paper
• Interaction of high-tech perinatal and ophthalmological centers as the basis for favorable outcomes of retinopathy of prematurity

  2024cites this paper
• Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity

  2024cites this paper
• A Narrative Review on Managing Retinopathy of Prematurity: Insights Into Pathogenesis, Screening, and Treatment Strategies

  2024cites this paper
• Term infant brain MRI after ROP treatment by anti-VEGF injection versus laser therapy.

  2024cites this paper
• Aflibercept to treat retinopathy of prematurity: need for more research

  2024cites this paper
• Timed topical dexamethasone eye drops improve mitochondrial function to prevent severe retinopathy of prematurity

  2024cites this paper
• Mitochondrial control of hypoxia-induced pathological retinal angiogenesis

  2024cites this paper
• Circulating VEGF-A Levels in Relation to Retinopathy of Prematurity and Treatment Effects: A Systematic Review and Meta-Analysis

  2024cites this paper
• Respiratory outcomes in preterm infants following intravitreal bevacizumab for retinopathy of prematurity–a 10-year matched case study

  2023cites this paper
• Comparison of Bevacizumab and Aflibercept for Suppression of Angiogenesis in Human Retinal Microvascular Endothelial Cells

  2023cites this paper
• Postnatal hyperglycemia alters amino acid profile in retinas (model of Phase I ROP)

  2023cites this paper
• Efficacy and Safety of Low Dose Intravitreal Ranibizumab for Treatment of Retinopathy of Prematurity

  2023cites this paper
• Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries

  2023cites this paper
• Laser versus Anti-VEGF: A Paradigm Shift for Treatment-Warranted Retinopathy of Prematurity

  2023cites this paper
• Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: A systematic review and meta-analysis

  2023cites this paper
• An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity

  2023cites this paper
• Bevacizumab for retinopathy of prematurity and neurodevelopment.

  2023cites this paper
• Short-term effects of intravitreal anti-vascular endothelial growth factor agents on body weight and multiple systems after treatment for retinopathy of prematurity

  2023cites this paper
• A Meta-Analysis of Neurodevelopmental Outcomes following Intravitreal Bevacizumab for the Treatment of Retinopathy of Prematurity

  2023cites this paper
• Eyesight to the Blind-Pharmacotherapy for Retinopathy of Prematurity.

  2023cites this paper
• Targeting the Mitochondrial Chaperone TRAP1 Alleviates Vascular Pathologies in Ischemic Retinopathy

  2023cites this paper
• Inhibition of VEGF-A expression in hypoxia-exposed fetal retinal microvascular endothelial cells by exosomes derived from human umbilical cord mesenchymal stem cells

  2023influential citation
• Long-Term Visual Prognosis of Patients Following Lens-Sparing Vitrectomy for Stage 4A Retinopathy of Prematurity

  2023cites this paper
• Electroretinographic Responses in Retinopathy of Prematurity Treated Using Intravitreal Bevacizumab or Laser: Electroretinography in Bevacizumab-treated ROP.

  2023cites this paper
• Comparison of intravitreal injection of ranibizumab versus bevacizumab for treatment of type 1 and aggressive retinopathy of prematurity in rural Egypt. A randomized clinical trial

  2022cites this paper
• Neurodevelopmental Outcomes for Retinopathy of Prematurity: A Nationwide Database Study.

  2022cites this paper
• A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept and Laser for Retinopathy of Prematurity.

  2022cites this paper
• Comparative Analysis of Intravitreal Ranibizumab versus Laser Therapy for Retinopathy of Prematurity

  2022cites this paper
• Applying Lucentis for the treatment of retinopathy of prematurity

  2022cites this paper
• Anti-vascular endothelial growth factor therapy in retinopathy of prematurity: An updated literature review

  2022cites this paper
• Intravitreal bevacizumab injection for retinopathy of prematurity and pulmonary hypertension

  2022influential citation
• New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics

  2022cites this paper
• Retinopathy of Prematurity: A Global Perspective and Recent Developments.

  2022cites this paper
• Retinopathy of prematurity: Metabolic risk factors

  2022cites this paper
• Plasma Levels of Bevacizumab and Vascular Endothelial Growth Factor After Low-Dose Bevacizumab Treatment for Retinopathy of Prematurity in Infants.

  2022cites this paper
• Novel Role of Prereplication Complex Component Cell Division Cycle 6 in Retinal Neovascularization

  2022cites this paper
• Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity.

  2022cites this paper
• Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes.

  2022cites this paper
• Comparative Study between Curcumin and Nanocurcumin Loaded PLGA on Colon Carcinogenesis Induced Mice

  2022cites this paper
• Serum vascular endothelial growth factor, insulin-like growth factor-1 and aflibercept levels in retinopathy of prematurity

  2022cites this paper
• Low-dose ranibizumab administration in retinopathy of prematurity

  2022cites this paper
• Noncoding RNAs as a novel approach to target retinopathy of prematurity

  2022cites this paper
• Effect of intravitreal bevacizumab for retinopathy of prematurity on weight gain

  2021cites this paper
• The Use of Bevacizumab in the Treatment of Retinopathy of Prematurity.

  2021cites this paper
• Low-Dose Ranıbızumab Admınıstratıon in Retınopathy of Prematurıty

  2021cites this paper
• Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF).

  2021cites this paper
• Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study

  2021cites this paper
• Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy

  2021cites this paper
• Complications of retinopathy of prematurity treatment

  2021cites this paper
• Neurodevelopmental Outcomes Associated With Intravitreal Bevacizumab Injections for Retinopathy of Prematurity

  2021cites this paper
• FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY

  2021cites this paper
• Cognitive Outcomes Following Intravitreal Bevacizumab for Retinopathy of Prematurity: 4- to 6-Year Outcomes in a Prospective Cohort.

  2021cites this paper
• Neurodevelopmental Outcomes in Preterm Infants with Retinopathy of Prematurity.

  2021cites this paper
• Ranibizumab in retinopathy of prematurity – one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study

  2021cites this paper
• Potential Effects of Nutraceuticals in Retinopathy of Prematurity

  2021cites this paper
• Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the Primary Modality of Treatment

  2021cites this paper
• Tear Fluid Angiogenic Factors: Potential Noninvasive Biomarkers for Retinopathy of Prematurity Screening in Preterm Infants

  2021cites this paper
• Association of Systemic or Intravitreal Antivascular Endothelial Growth Factor (Anti-VEGF) and Impaired Wound Healing in Pediatric Patients

  2021cites this paper
• INTRAVITREAL RANIBIZUMAB INJECTION AS TREATMENT IN PATIENTS WITH TYPE 1 RETINOPATHY OF PREMATURITY

  2021cites this paper
• Systemic conbercept pharmacokinetics and VEGF pharmacodynamics following intravitreal injections of conbercept in patients with retinopathy of prematurity

  2021cites this paper
• The Effect of Intravitreal Bevacizumab Dose on Retinal Vascular Progression in Retinopathy of Prematurity

  2021cites this paper
• Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors

  2021cites this paper
• Aggressive posterior retinopathy of prematurity: a review on current understanding

  2021cites this paper
• Recombinant thrombomodulin domain 1 rescues pathological angiogenesis by inhibition of HIF-1α-VEGF pathway

  2021cites this paper
• Neurodevelopmental Outcomes Following Anti-VEGF Treatment for ROP

  2021cites this paper
• The Short-Term Effects of Intravitreal Injection of Bevacizumab on the Plasma Levels of Vascular Endothelial Growth Factor, Insulin-Like Growth Factor-1, and Growth Parameters in Infants with Retinopathy of Prematurity

  2020cites this paper
• Treatment of retinopathy of prematurity (ROP) outside International Classification of ROP (ICROP) guidelines

  2020cites this paper
• Retinopathy of Prematurity: Evolving Treatment with anti-Vascular Endothelial Growth Factor.

  2020cites this paper
• Contralateral effect of systemic absorption of low dose bevacizumab (Avastin) after unilateral intravitreal injection in severe retinopathy of prematurity (ROP)

  2020cites this paper
• Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity.

  2020cites this paper
• Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions

  2020cites this paper
• Cardiovascular assessment after treatment for retinopathy of prematurity: a comparative study between anti-VEGF agent (aflibercept) and laser.

  2020cites this paper
• Epithelial Membrane Protein 2 (EMP2) Promotes VEGF-Induced Pathological Neovascularization in Murine Oxygen-Induced Retinopathy

  2020cites this paper
• Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity

  2020cites this paper
• Neurodevelopmental and Visual Outcomes in Infants with Retinopathy of Prematurity Treated with Bevacizumab and / or Laser Therapy

  2020cites this paper
• Therapie der Frühgeborenenretinopathie

  2020cites this paper
• Acute and chronic effects of intravitreal bevacizumab on lung biomarkers of angiogenesis in the rat exposed to neonatal intermittent hypoxia

  2020cites this paper
• Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis

  2020cites this paper
• Retinal Detachment After Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.

  2020cites this paper
• Update on the Use of Anti-VEGF Drugs in the Treatment of Retinopathy of Prematurity.

  2020cites this paper
• TNF‐α signaling regulates RUNX1 function in endothelial cells

  2020cites this paper
• Ocular Pharmacokinetics and Drug Delivery Challenges

  2020cites this paper
• Ranibizumab Population Pharmacokinetics and Free VEGF Pharmacodynamics in Preterm Infants With Retinopathy of Prematurity in the RAINBOW Trial

  2020cites this paper
• A safety review of drugs used for the treatment of retinopathy of prematurity

  2020cites this paper
• Ocular and Systemic Results of Intravitreal Bevacizumab Injection in Retinopathy of Prematurity Treatment

  2020cites this paper
• Neurodevelopmental Outcomes After Bevacizumab Treatment for Retinopathy of Prematurity-A Meta-Analysis.

  2020cites this paper
• Optimizing Measurement of Vascular Endothelial Growth Factor in Small Blood Samples of Premature Infants

  2019cites this paper
• Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment

  2019cites this paper
• Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.

  2019cites this paper